Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia

Inclusion Criteria: * Histologically confirmed\* diagnosis of 1 of the following: * Recurrent or refractory solid tumor or lymphoma (for patients in group 1) * Measurable or evaluable disease * Recurrent or refractory leukemia (for patients in group 2) * Greater than 25% blasts in the bone marrow (i.e., M3 bone marrow) * Active extramedullary disease allowed except leptomeningeal disease * Recurrent or refractory CNS tumor of 1 of the following types (for patients in group 3): * Neuroblastoma * Medulloblastoma/CNS primitive neuroectodermal tumor * Atypical teratoid rhabdoid tumor * No known curative therapy or therapy proven to prolong survival with an acceptable quality of life exists * No bone marrow involvement by disease (for patients in groups 1 and 3) * No active CNS leukemia * Performance status - Lansky 50-100% (for patients ≤ 10 years of age) * Performance status - Karnofsky 60-100% (for patients \> 10 years of age) * Absolute neutrophil count ≥ 1,000/mm\^3 (for solid tumor patients) * Platelet count ≥ 100,000/mm\^3\* (for solid tumor patients) (20,000/mm\^3\*\* for leukemia patients) * Hemoglobin ≥ 8.0 g/dL (RBC transfusion allowed) (for solid tumor and leukemia patients) * Triglycerides \< 300 mg/dL (for patients in group 3) * Bilirubin ≤ 1.5 times upper limit of normal (ULN) * ALT ≤ 5 times ULN * Albumin ≥ 2 g/dL * Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min * Creatinine based on age as follows: …